Maynard Um
-
-
-
-
-
-
-
RBC Capital Starts Praxis Precision Medicines Inc. (PRAX) at Outperform
-
-
-
-
-
-
-
Praxis Precision Medicines (PRAX) halted, news pending
-
-
-
-
-
-
-
Jefferies on Praxis Precision Medicines Inc. (PRAX): 'see 5%+ stock upside as FDA accepts the NDA for ulixacaltamide'
-
-
-
-
-
-
-
Wolfe Research Starts Praxis Precision Medicines Inc. (PRAX) at Outperform, Top Pick
-
-
-
-
-
-
-
Piper Sandler: 'Praxis Precision Medicines Inc. (PRAX) One of Our 2026 Best-Ideas'
-
-
-
-
-
-
-
TD Cowen: 'We view yesterday's announcement as highly positive for PRAX'
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
443,699 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

